Hormonal Replacement Therapy after Gynecologic Cancer Treatment
Thai Journal of Obstetrics and Gynaecology · 01.01.2023
DOI: 10.14456/tjog.2023.10 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thai Journal of Obstetrics and Gynaecology, erschienen am 01.01.2023. Verfasst von Banthisa Somboon.
Abstract (Originalsprache)
Patients diagnosed with gynecologic cancers are principally managed by radiation, chemotherapy, and total hysterectomy with bilateral salpingo-oophorectomy. The resultant loss of ovarian function associated with gynecologic cancer treatments poses major health concerns as patients face the long-term effects of early menopause. The health implication entails vasomotor symptoms, osteoporosis, cognitive impairment, and increased cardiovascular risks, to name a few. Patients with gynecologic cancers are likely to require intervention, as loss of ovarian function due to cancer treatments tend to produce more severe symptoms than those from natural menopause. Hormonal replacement therapy (HRT) has shown to be an excellent option for treating menopausal symptoms. However, initiating HRT remains a challenge due to the expression of hormone receptors in most gynecologic cancers. This article aims to provide current evidence regarding HRT in managing menopause after gynecologic cancer treatment.
Schlagwörter
Zitieren
APA
Somboon, B. (2023). Hormonal Replacement Therapy after Gynecologic Cancer Treatment. Thai Journal of Obstetrics and Gynaecology. https://doi.org/10.14456/tjog.2023.10
Vancouver
Somboon B. Hormonal Replacement Therapy after Gynecologic Cancer Treatment. Thai Journal of Obstetrics and Gynaecology. 2023. doi:10.14456/tjog.2023.10
BibTeX
@article{Somboon2023,
author = {Somboon, Banthisa},
title = {Hormonal Replacement Therapy after Gynecologic Cancer Treatment},
journal = {Thai Journal of Obstetrics and Gynaecology},
year = {2023},
doi = {10.14456/tjog.2023.10}
}
EUVIMED